Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT -0.30%63 Market Cap is $452.84 Mil as of Aug. 12, 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 861 Medical Devices & Instruments companies, ClearPoint Neuro ranks better than 67.48% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ClearPoint Neuro's share price for the quarter that ended in Jun. 2026 was $17.84. ClearPoint Neuro's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 30.17 Mil. Therefore, ClearPoint Neuro's market cap for the quarter that ended in Jun. 2026 was $538.18 Mil.
ClearPoint Neuro's quarterly market cap
declined
from Dec. 2025 ($401.77 Mil) to Mar. 2026 ($272.88 Mil) but then
increased
from Mar. 2026 ($272.88 Mil) to Jun. 2026 ($538.18 Mil).
ClearPoint Neuro's annual market cap
increased
from Dec. 2023 ($167.39 Mil) to Dec. 2024 ($424.75 Mil) but then
declined
from Dec. 2024 ($424.75 Mil) to Dec. 2025 ($401.77 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ClearPoint Neuro's Enterprise Value for Today is $487.42 Mil.
ClearPoint Neuro (NAS:CLPT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ClearPoint Neuro Market Cap Related Terms
ClearPoint Neuro Market Cap Historical Data
* Premium members only.
The historical data trend for ClearPoint Neuro's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ClearPoint Neuro's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Market Cap distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ClearPoint Neuro's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a Market Cap of $452.84 Mil as of Aug. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ClearPoint Neuro and its competitors. According to the industry distribution chart, ClearPoint Neuro ranks #280 out of 861 companies in the Medical Devices & Instruments industry, placing it in the top 32.5%.
Is ClearPoint Neuro's Market Cap too high?
ClearPoint Neuro's current Market Cap is $452.84 Mil. The Medical Devices & Instruments industry median Market Cap is 120.82. ClearPoint Neuro's value of $452.84 Mil is 274.8% above this industry median. Based on the distribution chart, ClearPoint Neuro ranks #280 out of 861 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Market Cap compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #280 out of 861 companies for Market Cap. This puts ClearPoint Neuro in the upper half of its industry. The industry median Market Cap is 120.82. ClearPoint Neuro's value of $452.84 Mil is 274.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 120.82, based on 861 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClearPoint Neuro's current Market Cap of $452.84 Mil is 274.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ClearPoint Neuro and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 120.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClearPoint Neuro's current Market Cap is $452.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $14.85 — trading 5% above its estimated fair value. The current Market Cap is $452.84 Mil and 274.8% above the Medical Devices & Instruments industry median of 120.82. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Market Cap is $452.84 Mil as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $14.85 is trading 5% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
Market Cap: $452.84 Mil
GF Value™: $14.14 vs. price of $14.85 (5% above fair value)
Industry Position: 274.8% above the Medical Devices & Instruments median (#280 of 861)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
